Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2011

View Archived Issues

Updated data disclosed from RADIANT-2 and -3 trials of everolimus in neuroendocrine tumors

PEP-02 shows clinical benefit in pancreatic and gastric cancer

Targeting of CD44 by miRNA-34a suppresses regeneration and metastatic potential of prostate CSCs

New antiviral agents claimed with activity against HAdV-37

European scientists develop new compounds targeting negative-sense ssRNA viruses

Dasatinib is not active in previously treated metastatic colorectal cancer

Antibodies against Glo-3A as a biomarker of celiac disease

Merck & Co. discloses new orexin OX2 receptor antagonists

Novel flourine-containing oligopeptides presented by Harvard College

Novartis develops novel PI3K-alpha inhibitors

Bristol-Myers Squibb offers update on fourth quarter 2010

New inhibitors claimed of RAC-alpha serine/threonine-protein kinase phosphorylation

Hutchison MediPharma begins phase I trial of fruquintinib in China

Oragenics plans second phase I trial of SMaRT replacement therapy

Phase IIb follow-up data show efficacy of KUR-111 in bone regeneration

Alexion acquires Taligen Therapeutics and expands portfolio

FDA sets PDUFA date for Transcept's Intermezzo NDA resubmission

Eisai receives complete response letter regarding NDA for new AcipHex formulation

EMA confirms eligibility of Omeros' OMS-103HP for centralized marketing application

BioMarin begins phase III trial of N-acetylgalactosamine 6-sulfatase in MPS IVA

Enrollment begins in phase II CP-4126 trial in gemcitabine-refractory pancreatic cancer

ToleroMune cat allergy T-cell vaccine shows efficacy in phase II trial

Lixisenatide demonstrates noninferiority to exenatide in phase III GetGoal-X trial

Rockwell Medical secures participation of two U.S. dialysis companies in phase III SFP trials

FDA requests additional trial of Contrave

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...